Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track RARE with free AI briefings, catalyst countdowns, and dilution alerts.

RARE · Ultragenyx Pharmaceutical Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$467M Cash on Hand
20mo Cash Runway
Follow RARE by email Get an email when RARE reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about RARE, unsubscribe in one click. Privacy

📣 What RARE Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Triheptanoin
FDA approved Jun 2020 · Dojolvi
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) Phase 3 · NCT05933200 Active not recruiting
Vestronidase Alfa
FDA approved Nov 2017 · Mepsevii
MPS VII N/A · NCT03775174 Available
Aceneuramic Acid Extended-Release Tablets Hereditary Inclusion Body Myopathy Phase 3 · NCT02736188 Terminated
Rebisufligene Etisparvovec MPS IIIA Phase 2/3 · NCT02716246 Recruiting
Setrusumab Osteogenesis Imperfecta Phase 3 · NCT06636071 Active not recruiting
Prophylactic Immunomodulatory (IM) Therapy MPS IIIA Phase 2/3 · NCT02716246 Recruiting
Prednisolone Glycogen Storage Disease Type IA Phase 3 · NCT05139316 Completed
Therapeutic Corticosteroid OTC Deficiency Phase 3 · NCT05345171 Active not recruiting
Optimized Prophylactic IM Therapy MPS IIIA Phase 2/3 · NCT02716246 Recruiting
Apazunersen Angelman Syndrome Phase 3 · NCT06617429 Terminated
Biphosphonate Osteogenesis Imperfecta Phase 3 · NCT05768854 Active not recruiting
Acetaminophen Glycogen Storage Disease Type III Phase 1/2 · NCT04990388 Terminated
ABO-102 MPS IIIA Phase 1/2 · NCT04088734 Terminated
UX053 Glycogen Storage Disease Type III Phase 1/2 · NCT04990388 Terminated
UX016 GNE Myopathy Phase 1/2 · NCT07511556 Recruiting
Triheptanoin oil Huntington Disease Phase 2 · NCT02453061 Completed

Also used in these trials (approved or third-party drugs, not RARE's own candidates): Sodium Acetate, Evinacumab, Adjuvant IM Therapy, Adjuvant Immunomodulatory (IM) Therapy, Zoledronic Acid, Burosumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

RARE holds $467M in cash and short-term investments (as of Sep 30, 2026) and burns about $70M/quarter from operations, an estimated runway of 20 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 8 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RARE files for a raise →

👥 Who Owns RARE

Insiders 3.6% Other 5%+ holders 6.2% Institutions (424 holders) 90.2% Public and other holders 0%
HolderTypeShares% of sharesAs of
Vanguard Portfolio Management Institution (13G, 5%+) 8,481,266 8.32% 2026-09-30
BlackRock, Inc. Institution (13G, 5%+) 8,141,384 7.99% 2026-06-30
RTW Investments, LP Institution (13G, 5%+) 7,796,895 7.65% 2026-06-30
STATE STREET CORPORATION Institution (13G, 5%+) 7,538,078 7.40% 2026-09-30
Madison Avenue International LP 5%+ holder (13G) 6,307,798 6.19% 2026-10-13
Vanguard Capital Management Institution (13G, 5%+) 5,058,419 4.96% 2026-06-30
Emil D Kakkis
President & CEO, Director · +132,693 options
Insider 2,694,724 2.64% 2026-04-16
Dennis Karl Huang
EVP, Chief Technical Operations Officer · +79,936 options
Insider 147,845 0.15% 2026-04-16
John Richard Pinion
EVP, Chief Quality Operations Officer · +79,936 options
Insider 133,142 0.13% 2026-04-16
Erik Harris
EVP & Chief Commercial Officer · +49,960 options
Insider 118,410 0.12% 2026-04-16
Eric Crombez
EVP and Chief Medical Officer · +59,952 options
Insider 111,189 0.11% 2026-05-05
Karah Herdman Parschauer
EVP and Chief Legal Officer · +49,960 options
Insider 92,562 0.09% 2026-08-03

Share count 101,924,068 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-08-04 FAYUVI NDA -25.3% +3.2% +7.1%
2025-08-18 — BLA +8.3% +0% +0.3%

Browse all historical PDUFA outcomes →

Get the full RARE picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RARE and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.